GSK's Jemperli gets EU nod for broader endometrial cancer use
Ticker: GLAXF · Form: 6-K · Filed: Dec 16, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Dec 16, 2024 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 7 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-approval, oncology, europe
Related Tickers: GSK
TL;DR
GSK's Jemperli + chemo gets EU green light for all advanced/recurrent endometrial cancer patients.
AI Summary
On December 16, 2024, GSK plc announced that Jemperli (dostarlimab) in combination with chemotherapy received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). This opinion recommends expanding the approval of Jemperli to include all adult patients diagnosed with primary advanced or recurrent endometrial cancer.
Why It Matters
This positive opinion from the CHMP could lead to wider access to Jemperli for a larger patient population in Europe, potentially increasing GSK's revenue from this drug.
Risk Assessment
Risk Level: low — This is a positive regulatory announcement regarding an existing drug, not a significant financial event or a new drug failure.
Key Players & Entities
- GSK plc (company) — Registrant and developer of Jemperli
- Jemperli (company) — Drug name
- dostarlimab (company) — Active ingredient in Jemperli
- CHMP (company) — Committee that issued the positive opinion
- December 16, 2024 (date) — Date of the announcement
FAQ
What is the specific recommendation from the CHMP regarding Jemperli?
The CHMP has issued a positive opinion recommending the expansion of Jemperli's approval to include all adult patients with primary advanced or recurrent endometrial cancer when used in combination with chemotherapy.
What is Jemperli?
Jemperli is a drug developed by GSK plc, and its active ingredient is dostarlimab.
What type of cancer does this recommendation pertain to?
The recommendation pertains to primary advanced or recurrent endometrial cancer in adult patients.
When was this announcement made?
The announcement was issued on December 16, 2024.
What is the significance of a positive CHMP opinion?
A positive CHMP opinion is a recommendation to the European Commission to approve a drug for a specific indication, paving the way for market authorization in the EU.
Filing Stats: 1,740 words · 7 min read · ~6 pages · Grade level 13.9 · Accepted 2024-12-16 08:24:34
Filing Documents
- a1210q.htm (6-K) — 53KB
- 0001654954-24-015544.txt ( ) — 55KB
SIGNATURES
SIGNATURES     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: December 16, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc